A3 cont

No. 9727135.7, filed December 22, 1997 and United Kingdom Application No. 9811037.2, filed May 22, 1998. --;

Immediately after page 71 and before the first page of claims (page 72), if appropriate, please insert the enclosed pages identified as --Sequence Listing--.

Please accept the enclosed printed version of the sequence listing, which is identical to the sequence listing submitted for parent application USSN 09/238,356, and the required Statements under 37 C.F.R. §1.821 (f) and (g) (below).

REMARKS

It is submitted that the claims herewith and the claims as originally presented are and were in full compliance with the requirements of 35 U.S.C. §§101, 102, 103 and 112. The addition and amendment of the claims herein are not made for the purpose of patentability within the meaning of 35 U.S.C. §§ 101, 102, 103 or 112; but rather the addition and amendment of the claims are made simply for clarification and to round out the scope of protection to which Applicants are entitled. Support for the amendments is found throughout the specification and from the originally-filed claims; no new matter is added.

This amendment is made to provide a lineage, including proper reference to the U.S. application of which this is a divisional application.

The Examiner's attention is respectfully drawn to the fact that the sequence listing in this application is identical to that of predecessor parent application U.S. Serial No. 09/238,356 filed January 27, 1999. It is respectfully requested that the U.S. PTO use the electronic version of the sequence listing in that prior application, making any necessary changes therein for this application, e.g., as to Serial Number and filing date.

It is believed that the Sequence Listing conforms to the requirements of 37 C.F.R. §1.823(b). The Statements required by 37 C.FR. §1.821(f) and (g) are set forth below. Pursuant to 37 C.F.R. §1.821(f), the undersigned attorney hereby states that the content of the paper copy submitted herewith, and the computer readable copy of the Sequence listing submitted in U.S. Serial No. 09/238,356 in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same. Pursuant to 37 C.F.R. §1.821(g), the undersigned attorney of record hereby states that this submission, filed in accordance with 37 C.F.R. §1.821(g), does not contain new matter. In view of the amendments, remarks and enclosures herewith, the application complies with the

requirements for computer readable disclosure of the biological sequences under 37 C.F.R. §1.821-1.825.

However, if any fees are required, or if any overpayment has been made, please charge such fee, or credit any overpayment, to Deposit Account 50-0320.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

By: ______________________

Thomas J. Kowalski

Reg. No. 32,147

APPENDIX 1: MARKED-UP VERSION OF AMENDMENTS

IN THE SPECIFICATION:

Specification, at page 1, the first sentence of the first paragraph (under "RELATED APPLICATIONS"):

-- This is a Divisional Application of allowed United States Patent Application No. 09/238,356, which is a Continuing Application of PCT/GB98/03876, filed December 22, 1998, claiming priority to United Kingdom Application No. 9727135.7, filed December 22, 1997 and United Kingdom Application No. 9811037.2, filed May 22, 1998. ---.

IN THE CLAIMS:

10. (amended) A retroviral vector according to [any preceding] claim 9 which comprises at least one component from an equinine lentivirus.

16. (amended) A retroviral particle obtainable from the retroviral vector of [any one of claims 1 to 12 or claim 14 or 15] claim 9 or 15.

17. (amended) A retroviral particle obtainable from the retroviral vector of [any one of claims 1 to 12 or claim 14 or 15] claim 9 or 15.

18. (amended) A cell transfected or transduced with a retroviral vector according to [any one of claims 1 to 12 or claim 14 or 15 or a retroviral particle of claim 16] claim 9 or 15.

19. (amended) A retroviral vector according to [any one of claims 1 to 12 or claim 14 or 15 or a retroviral particle of claim 16 or a cell according to claim 17] claim 9 or 15 for use in medicine.

20. (amended) Use of a retroviral vector according to [any one of claims 1 to 12 or claim 14 or 15 or a retroviral particle of claim 16 or a cell according to claim 17] claim 9 or 15 for the manufacture of a pharmaceutical composition to deliver an NOI to a target site in need of same.

21. (amended) A method comprising transfecting or transducing a cell with a retroviral vector according to [any one of claims 1 to 12 or claim 14 or 15 or a retroviral particle of claim 16 or by use of a cell according to claim 17] claim 9 or 15.

22. (amended) A delivery system in the form of a retroviral vector according to [any one of claims 1 to 12 or claim 14 or 15 or a retroviral particle of claim 16 or a cell according to claim 17] claim 9 or 15.

23. (amended) A delivery system for a retroviral vector according to [any one of claims 1 to 12 or claim 14 or 15 or a retroviral particle of claim 16 or a cell according to claim 17] claim 9 or 15 wherein the delivery system comprises a non-retroviral expression vector, an adenovirus and/or a plasmid.